

Seeking Victory in the Fight Against Ovarian Cancer

May 2025 Corporate Presentation

Forward-Looking Statements

These slides and the accompanying oral presentation contain forward-looking statements and information. Forward- looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may", "might", "will", "should", "could", "expect", "plan", "anticipate", "believe", "estimate", "project", "intend", "future", "potential" or "continue", and other similar expressions are intended to identify forward looking statements. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of our securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, any of our securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any investor.



Our Mission

We are advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women



Highlights

Lead product candidate (KAD101, best-in-class next generation prolactin antagonist) indication: platinum resistant ovarian cancer (PROC)

90% of patients are in need for an effective treatment

Targeting Primary Cause of Hormone-Driven Cancers: Prolactin

KAD101 demonstrated promising initial human clinical data

Leadership has <u>extensive preclinical, clinical, and drug development</u> <u>experience/expertise</u> to execute clinical development plan

Targeting prolactin; over expressed in ~80% of patients with ovarian cancer¹

Kaida SAB lead, Anil K. Sood, MD – MDACC², is internationally recognized PROC KOL and leading expert on prolactin (PRL) biology

KAD101 Phase 1 study initiation expected Q4 2026/Q1 2027

Pipeline expansion opportunity into Breast and Uterine cancer. Prolactin over expressed in ~90% of patients³

1. V. Levina et al. Biological Significance of Prolactin in Gynecologic Cancers. Cancer Res 15 June 2009; 69 (12): 5226–5233. https://doi.org/10.1158/0008-5472.CAN-08-4652; 2. MDACC: The University of Texas MD Anderson Cancer Center 3. Faupel-Badger et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014 Feb;5(1):42-50. doi: 10.1007/s12672-013-0165-7. Epub 2013 Nov 19. PMID: 24249584; PMCID PMC3906637.

Kaida Management Team and Advisors

Proven leadership with drug development and business experience... Dr. Stella Vnook **Craig Pierson Pam Swiggard Jay Campbell** John Langenheim, PhD **Co-Founder** Chairman, Co-Founder **CSO.** Co-Founder **Regulatory Affairs** CFO/COO Major Biopharma LifeTech Capital, Founder Prolactin Receptor Accomplished Executive, of AiM Medical Robotics Antagonist Subject Matter pharmaceutical executive Expert, Assistant Professor of Transformational Leader MSE/CE Life Science in global regulatory affairs financial, business/ with Extensive Pharma Banker for 26 Years Cancer Biology for Sidney and quality assurance Kimmel Medical College at Background, Doctorate in and operational roles Economics of PH and Thomas Jefferson University Pharmacy and MBA CRI Cancer Research Institute-Thomas Jefferson Vella Galera Zynerba 😞 Likarda* MERCK MEDICAL University COLLEGE

Jazz Pharmaceuticals. Catalent.

Head of Scientific Advisory Board

Anil K. Sood, M.D.

David Rosen. J.D.

FDA and Reg Affairs Expert


THE UNIVERSITY OF TEXAS MDAnderson

FOLEY

Cancer Center

Scientific and Regulatory Expert Advisors

- Internationally Recognized KOL in Gynecologic Oncology and Cancer Biology
- **Professor and Vice Chair for Trans. Research Depart. Gynecologic Oncology** ٠
- Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and Co-leads the Ovarian Cancer Moon Shot Program at MD Anderson
- Partners and public policy lawyer with Foley & Lardner LLP ٠
- Background in pharmacy and law, and 14 years of regulatory experience at the Food and Drug ٠ Administration (FDA) and expert on strategic guidance on FDA submissions
- FDA Council, Former FDA Panel Member, Author of Orange Book



Experienced life sciences executive and leader in corporate development,

CONCARLO

koltan

Kaida Scientific and Clinical Advisor: Anil K. Sood, M.D.

Internationally Recognized KOL in Gynecologic Oncology and Cancer Biology



Anil K. Sood, M.D.

Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery

University of Texas MD Anderson Cancer Center

ities (6, 7), the full-length PRLR gene product was not detected in

Structurally, the extracellular ligand-binding domains are highl conserved and retain PRL-binding activity, while the membri

ors in mediating PRL signaling in can

Check for spokes

MOLECULAR CANCER THERAPEUTICS

Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer

Yunfei Wen¹, Ying Wang², Anca Chelariu-Raicu¹, Elaine Stur¹, Yuan Liu^{1,3}, Sara Corvigno¹, Faith Bartsch⁴, Lauren Redfern¹, Behrouz Zand¹, Yu Kang¹, Jinsong Liu⁵, Keith Baggerly², and Anil K. Sood

Abnormal activity of human prolactin (PRL) and its mem- PTEN^{war} orthotopic mouse models of uterine cancer. In com-

Absemble activity of human productin (PR12) and him these programs of human strates activity of representing the strates activity of human strates human strates human

Introduction Human production (PRL) acts primarily to regulate the neurant functions of the funder reproduct was primarily to resplate the neurant intension of the funder reproduct was primarily to the solution primarily primarily processes drawn (L). Use's of cristical materials and the solution primarily processes drawn (L). To evide of cristical materials primarily and processes drawn (L). To evide of cristical materials and the solution of the solution primarily the solution of the solution of the solution of the solution primarily primarily the solution of the solution of the solution of the solution primarily primarily the solution of the solution of the solution primarily primarily the solution of the

PBI, are determined in generologie multiple cardination of the second programment of the seco

as ND Anderson Cancer Center, Houssen, Teas. "Desamment of proximal region, including the transmission and intra can disconstantical Biology. The University of Teas. MD Ander-cellular domains and intra cellular domains, varies between isoforms this variation contributes to dorter. Houston, Ceas. "Department of Biologines, RN double of University and University in Provide Center (Center Center) and Center (Center) and Ce

a bolog, run burwing of isaa ya Anania an observationed Bolokinone, Ricc Juive att of Physician Assiztate Studies, Geopa no, C2: "baparitiment Bolikoliga, Tubi netter Centre, Houstin, Team. The ortice or available et Molocial Centre Is ortice or available et Molocial Centre File and Centre Centre Centre Centre Centre Centre et al. Survival and Expendence Centre Centre et al. Survival and Expendence Centre Centre et al. Survival and Expendence Centre et al. Survival et al. Survival et

Introduction

Cell Reports

Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death

ouz Zand,¹ Bulent Ozpolat,²² Mirosław J. Szczepanski,¹¹ Chunhua Lu,¹ Erkan Yuca,² Amy R. C handra Bartholomeusz,² Ibrahim Tekederell,² Yu Kang, ¹ Rajesha Rupalimool,¹ Chad V. Peeot Anaduce Hermandez,¹³ Anna Lokkhin,² Suan K. Lutgendorf,² Jinsong Lui,¹⁴ Walter N. Hitker briel Lopez-Berestein,³² Marta Szajnik,¹² Naoto T. Ueno,³ Robert L. Coleman,¹² and Anil K. Soc Seck Oncology, The University of Texas MD Anderson Canc Veck Oncology, The University of Texas MD Ander University of Texas MD Anderson Cancer Center, risity of Texas MD Anderson Cancer Center. How

Ittsburgh Cancer Institute, Pittsburgh, PA 15213, USA etrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA Jernson University, Clemson, SC 29634, USA au University of Warsiaw, Warsaw 02-091, Poland University of Medical Sciences, Poznan e ersity of Houston, Houston, TX 77024, US

SUMMARY	including ovarian and endometrial cancers (Levina et al., 2009;
Therapevil upped afters of near-nearborhage is can be called provides an alternative mechanism for call death. Protectin (PRL) and its nearborhage (PRL) considered attractive therapevil tempts because of their noise up works of 2004. The provide and pro- ting of the provide of 2004 interactive provides and provide the provide of 2004. The provide and pro- perticular and provide the turner approximate in a provide the provide of 2004. The provide the pro- reducing the provide of 2004 interactive provides in the provide the provide of 2004 interactive provides and the provide of 2004 interactive provides and the provide the provides and the provides and the provide the provides and the provides and the provide the provides and th	More et al., 2003, Timori et al. 2011 (L. Hanna PRL, Itaa poppeleter- ing all the site is non-investment and construct across of the site is non-investment and the site is a site of the site is a site of the si
The multifunctional hormone, prolactin (PRL), is not only essen- tial for normal reproduction and maintenance of pregnancy but also contributes to pathogenesis of gynecologic malignances,	2010: White et al., 2010). Targeted molecular therapies that can induce sustained autophagy offer new therapeutic opportunities (Shimizu et al., 2004), particularly in breast,
488 Call Deports 7, 488-500, April 24, 2014 (2014 The Authors	



Net: Sopherstry dot for this store is public at Motion 2004 and an annual start annumentary and an annual start annumentary and an annual start annumentary and annual start annumentary annual start annual start annumentary annual start annual start annual start annual start annual start annumentary annual start a 2020 American Association for Cancer Research

Note: Supplementary data for this article are available at Molecular Cancer to Therapeutics Online (http://mct.aacrjournals.org/).

AACER American Association for Cancer Research

ve been shown to docrine PRL activ-PRLR isoforms, while the other is a noncoding transcript variant

blood

301. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS, AND PLATELET ADHESION, ACTIVATION, AND BIOCHEMISTRY | NOVEMBER 29, 2018

Platelets Promote Activation of the Complement System in Ovarian Cancer

Omavra Gonzalez Pagan, MD.¹ Min Soon Cho, PhD. Vahid Afshar-Kharghan, MD ¹UT Houston - McGovern Medical School, Houston, TX ²MD Anderson Cancer Center, Houston, TX ³M.D. Anderson Cancer Center, Houston, TX

Blood (2018) 132 (Suppl_1) : 4970. http://doi.org/10.1182/blood-2018-99-116752

Abstract


Platelets promote metastasis and growth of ovarian cancer. We have shown that platelets extravasat into the tumor microenvironment (TME) and increase proliferation and epithelial-mesenchymal transition (EMT) in ovarian cancer cells. We have also shown that activation of the complement system in TME of ovarian cancer enhances tumor growth. Ovarian cancer cells secrete complement proteins that upon activation in the TME increase proliferation of cancer cells and promote EMT via an autocrine pathway. The activators of the complement system in the TME have not been identified. We have demonstrated that upon activation platelets activate the complement system on their surface. In the current study, we examined whether extravasated platelets inside tumors contribute to the complement activation in the TME

1) We examined the effect of antiplatelet reagents on platelet extravasation into TME, using murine models of ovarian cancer. Tumors induced by injection of ovarian cancer cells into the peritoneum of Nu Nu mice were resected after 6-8 weeks and the number of extravasated platelets was determined by immunostaining tumor sections and counting the number CD42 (GPIb) positive cells that were outside the blood vessels (CD31 positive). We found that platelet extravasation is an active process and platelet inhibition by aspirin or ticagrelor reduces the number of extravasated platelets. Furthermore, P2Y12 deficient platelets extravasate less than normal platelets. In all of these experiments, the number of





Development Pipeline





Ovarian Cancer

Patient Journey is Grim & Needs a Solution to Improve Outcomes

Typically identified when already late stage making treatment difficult and costly. Our focus is to target the cause that created the cancer.

Market Opportunity¹

\$3.7B Current therapies have limited efficacy but represent large market

\$6.4B Expected to grow at a 14.4% CAGR in 2024

Therapeutics that offer a durable response





Consistently Poor Results Across Therapies

Underpins Need for New Innovative Approach

Drug	Target	% of Patients Expression			ORR	mPFS (mo)	mOS (mo
KAD101 KAD102	Prolactin	~80%			KA	IDA Opportu	nity
Abbvie: Elahere	FR-Alpha ≥75%	~25-30%			42%	5.6	16.5
Sutro: Luvelta	FR-Alpha ≥25%	~60-80%			~38%	NA	NA
Corcept: Relacorilant	Glucocorticoid Receptor (GR)	~40%			33%	5.6	13.9
Checkpoint Inhibitors	PD-(L)1	~10-20%			~5-15%	2.1-3.5	11.8-18.7
			C	hemo	~15-20%	~3.5 Average	~13.4 Average
Mersana: Upfitamab	NaPi2b	~50%			13%	Study	Failed
KAIDA Bio Pharma							9

KAD101 Initially Targeting Ovarian Cancer

Novel Biologic that Blocks the Prolactin Receptor to <u>Prevent Cancer Cell</u> <u>Growth Signals, Incite Autophagy, and</u> <u>Re-sensitization to Chemotherapies</u>

- Novel encapsulated formulation of derisked asset, KAD101, which has seen promising initial human clinical data
- Multiple expansion opportunities into endometrial, uterine and breast cancers
- Opportunity as maintenance therapy

Prolactin

Higher Expression Correlates with Reduced Survival Contributing to Tumor Growth and the Development of Malignancies

OF

H₃CO

H₃CO

Targeting Prolactin

- Potential to disrupt tumor growth and reverse the process through autophagy
- KAD 101 prevents prolactin receptor dimerization

Impact on Cell Signaling

 Involved in pathways like JAK/STAT5 and PI3K/Akt, essential for cell proliferation

Chemotherapy Resistance

The down-regulation of GST is directly linked to chemotherapy resistance, making patients receptive again, a major treatment hurdle



OH

OCH₃

OCH_a

Differentiated Mechanism of Action

KAD101 represents a longer half life molecule that blocks the prolactin receptor to prevent cancer cell growth signals and initiate autophagy

Activates Autophagy

Triggers cell 'self-eating' process, leading to the death of cancer cells


Cell Proliferation Halted

Inhibits the Jak2 pathway, which is crucial for cancer cell multiplication


Chemoresistance Addressed

• Downregulates GST enzyme, which has shown to reactivate response to chemotherapy in chemo-resistant patients

Autophagy: Programmed Cell Death



Downregulates GST: Chemoresistance





G129R⁽¹⁾ First-In-Human Phase 1 Clinical Data

First cohort of subtherapeutic dosing resulted in <u>therapeutic benefit/signal observed</u> in all patients <u>with clean safety profile/low toxicity</u>

Patient 1

- Received Taxol with Neulasta
- Had 2 significant RECISTmeasured tumors
- Stable disease achieved; no new cancer growths observed (day 29)
- Treatment with low-dose deemed effective

Notes:

Patient 2

- Treatment history includes Taxol, Carboplatin, and Doxil
- Presented with one large RECIST-measured tumor
- Tumor shrank to nonmeasurable size post-KAD101 treatment (day 29)
- Demonstrated significant response to low-dose

Patient 3

- Prior treatments: Gemzar, Carboplatin, Doxil, Avastin
- Started the three RECISTmeasured tumors
- Post-treatment, all three tumors reduced by 15-20% in size (day 29)
- Showed a marked reduction in tumor volume

KAD101 development addressing two key limitations of G129R, extremely short circulation half-life and necessity of daily injections




(1) G129R (PRL antagonist) dosage administered to three enrolled patients in Phase 1 clinical trial, Oncolix, Inc. sponsor, was initial (lowest) dose intended as part of the three doses planned to be evaluated in the (dose escalation) study


G129R Preclinical Experiments

Preclinical data of KAD101 + standard of care therapies highlight therapeutic synergy


G129R Potentiates Herceptin Effects in T-47D Xenografts in Nude Mice⁽¹⁾



T-47D cells (8.5 x10⁶) were injected in the mammary fat pad of female nude mice. One week after tumor cell inoculation, G129R (4 mg/kg/daily) or Herceptin (4 mg/kg/bi-weekly), or a combination of both were injected i.p. for 4 weeks. Measurements of tumor growth were recorded once a week. Each value is a mean \pm SD of 6-8 mice/group. ** P < 0.01 and * P < 0.05 versus control; \pm P < 0.05 versus Herceptin alone.



G129R Inhibited Tumor Growth in Ovarian Cancer Models⁽²⁾



G129R Inhibited Tumor Growth in Ovarian Cancer Models

(A) Left, PRLR-LF was detected in HeyA8 and SKOV3 cells treated with PRL (0.1 mg/ml), G129R (10 mg/ml), a combination (PRL+G129R), or control (CTL). Right, the fold gel density was normalized to that of b-actin.

(B) Effects of G129R and paclitaxel on tumor growth in HeyA8 and SKOV3 orthotopic mouse models. Weight of the tumor from each mouse is shown; left, HeyA8: *p < 0.05 (CTL versus G129R); **p < 0.001 (CTL versus G129R+paclitaxel). Right,

SKOV3: *p < 0.05 (CTL versus G129R); **p < 0.001 (CTL versus G129R+paclitaxel).

(C) Left, representative images of cleaved caspase-3 in HeyA8 tumor tissues (inset shown at 2003 magnification); the scale bar represents 100 mm. Results were confirmed with triplicate experiments. Right, percentage of tumor with cleaved caspase-3 staining is shown graphically (error bar = 95%

confidence interval); differences between groups were compared by unpaired two tailed t test: n = 5, *p < 0.05 (paclitaxel versus G129R+paclitaxel).

14

Accomplished & Upcoming Milestones

Completed

- Preclinical translational studies
- Re-formulation for KAD101 and IP through partner
- Regulatory path/strategy established
- Patents filed with further IP filings
- SAB in place with Dr Anil Sood from MD Anderson
- Commence manufacturing of KAD101 with US Based CDMO

Upcoming Milestones and Events

- Re-open Existing IND. Securing Type C development meeting
- Complete animal "bridging" studies for the new formulation
- KAD101 limited drug substance toxicity studies anticipated
- Sponsored Research Agreement with MD Anderson
- Expanding IP portfolio with additional patent filings
- KAD101 Phase 1 study initiation expected Q4 2026/Q1 2027







Peer Valuations Suggest Potential for Significant Upside, Even at Earlier Stages

Company	Drug	Phase	ORR	mPFS (mo)	mOS (mo)	Deal Price / Market Cap	
Acquisitions							
immun•gen.	WELAHERE' investigational sorratasiane-gync injection 100 ng	Approved	42%	5.6	16.5	\$10.1 Billion Acquired by ゐbb∨ie	
Profound Bio	Rinatabart sesutecan: FR-alpha ADC	Phase 1/2	NA	NA	NA	\$1.8 Billion Acquired by Genmab	
Public Companies							
SUTR: BIOPHARMA	Luvelta	Phase 2/3	~38%	NA	NA	\$350 Million	
Corcept	Relacorilant	Phase 2	33%	5.6	13.9	\$2.8 Billion	
zentalis [.]	Azenosertib	Phase 1/2		Study Ongoing		\$825 Million	
Nuvation Bio	NUV-1511	Phase 1/2		Study Ongoing		\$825 Million	
: SHATTUCK	SL-172154	Phase 1	9%	9%		\$500 Million	
	MGC026	Phase 1		Study Ongoing		\$280 Million	
Recent Private Financings Underscores Interest and Value in Ovarian Cancer Space							
Company	Drug	Phase	Last Round	Total Raise	Tota	l Raise to Date	
T T R L BIOTHERAPEUTICS	TORL-1-23: Claudin-6 ADC	Phase 1	Series B	\$158 Million		\$350	



Highlights

Lead product candidate (KAD101, best-in-class next generation prolactin antagonist) indication: platinum resistant ovarian cancer (PROC)

90% of patients are in need for an effective treatment

Targeting Primary Cause of Hormone-Driven Cancers: Prolactin

KAD101 demonstrated promising initial human clinical data

Leadership has <u>extensive preclinical, clinical, and drug development</u> <u>experience/expertise</u> to execute clinical development plan

Targeting prolactin; over expressed in ~80% of patients with ovarian cancer¹

Kaida SAB lead, Anil K. Sood, MD – MDACC², is internationally recognized PROC KOL and leading expert on prolactin (PRL) biology

KAD101 Phase 1 study initiation expected Q4 2026/Q1 2027

Pipeline expansion opportunity into Breast and Uterine cancer. Prolactin over expressed in ~90% of patients³

1. V. Levina et al. Biological Significance of Prolactin in Gynecologic Cancers. Cancer Res 15 June 2009; 69 (12): 5226–5233. https://doi.org/10.1158/0008-5472.CAN-08-4652; 2. MDACC: The University of Texas MD Anderson Cancer Center 3. Faupel-Badger et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014 Feb;5(1):42-50. doi: 10.1007/s12672-013-0165-7. Epub 2013 Nov 19. PMID: 24249584; PMCID PMC3906637.



Thank You!

Dr. Vnook KAIDA BioPharma Email: <u>skvnook@gmail.com</u> www.KAIDA-BioPharma.com

Glossary of Terms

Autophagy	A process where cells recycle their components to stay healthy and respond to stress.
CAGR	Compounded Annual Growth Rate: The annualized average growth rate of an investment or metric over a specified period.
Cell Proliferation	The process by which cells divide and multiply, leading to growth or tissue repair.
Chemoresistance	The ability of cancer cells to resist the effects of chemotherapy.
Endometrial Cancer	Cancer that begins in the lining of the uterus (endometrium).
GST Enzyme	Glutathione S-transferase: An enzyme involved in detoxifying harmful compounds within cells.
Half-Life	The time it takes for a substance, like a drug, to reduce to half its original amount in the body.
Jak2 Pathway	A signaling pathway involved in cell growth and development, often linked to certain cancers.
Malignancy	Cancerous growth that can spread to other parts of the body.
mOS	Medium overall survival.
Orphan Drug Designation	A special status for drugs targeting rare diseases affecting fewer than 200,000 patients in the U.S., providing 7 years of market exclusivity.
ORR	Overall Response Rate: The percentage of patients whose cancer shrinks or disappears due to treatment.
Ovarian Cancer	Cancer that begins in the ovaries, part of the female reproductive system.
PFS	Progression Free Survival: The length of time during and after treatment that a patient's cancer does not worsen.
Platinum-Resistant Ovarian Cancer (PROC)	A type of cancer that does not respond well to platinum-based chemotherapy.
Prolactin	A hormone primarily responsible for stimulating milk production in mammals.
RECIST-measured	A standard way to measure tumor response to treatment, using defined criteria.
SRA	Sponsored Research Agreement.
Tumor	An abnormal mass of tissue resulting from uncontrolled cell growth.
Uterine Cancer	Cancer that starts in the uterus, commonly involving the endometrium.

